Vote Scores

Home / Companies / scPharmaceuticals Inc. / 3 Jun 2025

Meeting · year to 30 June 2025130 filers reporting

scPharmaceuticals Inc.: meeting of 3 Jun 2025

Votes reported on Form N-PX, item by item

130 Form N-PX filers reported votes at the scPharmaceuticals Inc. meeting of 3 Jun 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

3 nominees; 70.8% of reported votes for; 21 filers withheld from or voted against at least one nominee.

270 vote records from 47 filers. 14 of the 46 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

68.1% for0.0% against31.9% other30.4% against management47 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

188 vote records from 130 filers. 4 of the 125 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

93.1% for3.1% against3.8% other3.2% against management130 filers100.0% for0.0% against0.0% against management23,423,207 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

90 vote records from 47 filers. 0 of the 46 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

97.9% for0.0% against2.1% other0.0% against management47 filers100.0% for0.0% against0.0% against management2,455,657 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForForFor
DimensionalNo reportAgainst *No report
State Street and SPDRForForFor
InvescoNo reportForNo report
EquitableForForFor
Charles SchwabForForFor
Nuveen and TIAAForForFor
ProShares and ProFundsAbstain or withhold *ForFor
John Hancock and ManulifeAbstain or withhold *ForFor
Morgan Stanley, Eaton Vance and CalvertAbstain or withhold *ForFor
J.P. MorganNo reportForNo report
Goldman SachsAbstain or withhold *ForFor
PGIM and PrudentialNo reportForNo report
Northern Trust and FlexSharesForForFor
SEINo reportForNo report
T. Rowe PriceForForFor
ThriventAbstain or withhold *ForFor
Lincoln FinancialForForFor
NationwideForForFor
Victory CapitalAbstain or withhold *ForFor
Guggenheim and RydexAbstain or withhold *ForFor
Columbia ThreadneedleForForFor
BNY MellonNo reportForNo report
PrincipalNo reportForNo report
Pacific Life fundsForForFor
Global XForForFor
AllianceBernsteinNo reportForNo report
DWSAbstain or withhold *ForFor
Neuberger BermanNo reportForNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the scPharmaceuticals Inc. meeting?

130 Form N-PX filers reported votes at the meeting of 3 Jun 2025. On say-on-pay, 4 of 125 voted against management (3.2%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by scPharmaceuticals Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for scPharmaceuticals Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing scPharmaceuticals Inc. with a meeting date within three days of 3 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 30 Sep 2026.